Details for Patent: 11,052,196
Which drugs does patent 11,052,196 protect, and when does it expire?
Patent 11,052,196 protects BYNFEZIA PEN and is included in one NDA.
Summary for Patent: 11,052,196
| Title: | Method of injecting octreotide acetate into the body |
| Abstract: | A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 μg/mL. The method further includes providing, on the injector, a plurality of indicia only at prescribed doses of 50 μg, 100 μg, 150 μg and 200 μg settable via the dose setter without indicia between said prescribed doses; and permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter, wherein the injector is configured to provide at least one audible feedback during the rotation. |
| Inventor(s): | Satyashodhan Babasaheb Patil, Sudeep Kumar Agrawal |
| Assignee: | Sun Pharmaceutical Industries Ltd |
| Application Number: | US17/087,670 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Dosage form; |
Drugs Protected by US Patent 11,052,196
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | BYNFEZIA PEN | octreotide acetate | SOLUTION;SUBCUTANEOUS | 213224-001 | Sep 27, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING ACROMEGALY PATIENTS WHO HAVE HAD INADEQUATE RESPONSE TO OR CANNOT BE TREATED WITH SURGICAL RESECTION, PITUITARY IRRADIATION, AND BROMOCRIPTINE MESYLATE AT MAXIMALLY TOLERATED DOSES | ⤷ Start Trial | ||||
| Sun Pharm | BYNFEZIA PEN | octreotide acetate | SOLUTION;SUBCUTANEOUS | 213224-001 | Sep 27, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING PROFUSE WATERY DIARRHEA ASSOCIATED WITH VASOACTIVE INTESTINAL PEPTIDE TUMORS (VIPOMAS)-SECRETING TUMORS | ⤷ Start Trial | ||||
| Sun Pharm | BYNFEZIA PEN | octreotide acetate | SOLUTION;SUBCUTANEOUS | 213224-001 | Sep 27, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD OF TREATING SEVERE DIARRHEA AND FLUSHING EPISODES ASSOCIATED WITH METASTATIC CARCINOID TUMORS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
